Mutant N-RAS protects colorectal cancer cells from stress-induced apoptosis and contributes to cancer development and progression

Y Wang, S Velho, E Vakiani, S Peng, AJ Bass, GC Chu… - Cancer discovery, 2013 - AACR
Y Wang, S Velho, E Vakiani, S Peng, AJ Bass, GC Chu, J Gierut, JM Bugni, CJ Der
Cancer discovery, 2013AACR
N-RAS is one member of a family of oncoproteins that are commonly mutated in cancer.
Activating mutations in NRAS occur in a subset of colorectal cancers, but little is known
about how the mutant protein contributes to the onset and progression of the disease. Using
genetically engineered mice, we find that mutant N-RAS strongly promotes tumorigenesis in
the context of inflammation. The protumorigenic nature of mutant N-RAS is related to its
antiapoptotic function, which is mediated by activation of a noncanonical mitogen-activated …
Abstract
N-RAS is one member of a family of oncoproteins that are commonly mutated in cancer. Activating mutations in NRAS occur in a subset of colorectal cancers, but little is known about how the mutant protein contributes to the onset and progression of the disease. Using genetically engineered mice, we find that mutant N-RAS strongly promotes tumorigenesis in the context of inflammation. The protumorigenic nature of mutant N-RAS is related to its antiapoptotic function, which is mediated by activation of a noncanonical mitogen-activated protein kinase pathway that signals through STAT3. As a result, inhibition of MAP–ERK kinase selectively induces apoptosis in autochthonous colonic tumors expressing mutant N-RAS. The translational significance of this finding is highlighted by our observation that NRAS mutation correlates with a less favorable clinical outcome for patients with colorectal cancer. These data show for the first time the important role that N-RAS plays in colorectal cancer.
Significance: Little is known about N-RAS function in normal biology or in cancer. Our study links the antiapoptotic function of mutant N-RAS to its ability to promote colorectal cancer in an inflammatory context. In addition, our study pinpoints a therapeutic strategy for this distinct colorectal cancer subtype. Cancer Discov; 3(3); 294–307. ©2013 AACR.
This article is highlighted in the In This Issue feature, p. 239
AACR